1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow ALK-TKI: new trials by email Literature Review of ALK-TKI trials Research Report on ALK-TKI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia Timolol 0.5% eye drops and betamethasone valerate 0.1% cream, Betamethasone valerate 0.1% cream - Paronychia, EGFR-TKI | Phase 3 | Recruiting | Queen Mary Hospital, Hong Kong | 40 | 2024-10-09 | 2024-10-18 |
Paronychia (1)
Infections (1) · Nail Diseases (1) · Skin Diseases (1) · Skin Diseases, Infectious (1) · Skin and Connective Tissue Diseases (1)
Betamethasone Valerate (1) · Ophthalmic Solutions (1) · Timolol (1)
Queen Mary Hospital, Hong Kong (1)
Hong Kong (1)